Changes in fat and lean body mass during androgen-deprivation therapy for prostate cancer.

[1]  Sara Espinoza,et al.  Frailty in older adults: insights and interventions. , 2005, Cleveland Clinic journal of medicine.

[2]  J. Eastham,et al.  Randomized controlled trial of zoledronic acid to prevent bone loss in men receiving androgen deprivation therapy for nonmetastatic prostate cancer. , 2003, The Journal of urology.

[3]  K. Courneya,et al.  Resistance exercise in men receiving androgen deprivation therapy for prostate cancer. , 2003, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[4]  S. Cerutti,et al.  Changes in bone mineral density, lean body mass and fat content as measured by dual energy x-ray absorptiometry in patients with prostate cancer without apparent bone metastases given androgen deprivation therapy. , 2002, The Journal of urology.

[5]  Anthony L Zietman,et al.  Changes in body composition during androgen deprivation therapy for prostate cancer. , 2002, The Journal of clinical endocrinology and metabolism.

[6]  M. Parmar,et al.  The effects of induced hypogonadism on arterial stiffness, body composition, and metabolic parameters in males with prostate cancer. , 2001, The Journal of clinical endocrinology and metabolism.

[7]  J. Stanford,et al.  Quality-of-life outcomes after primary androgen deprivation therapy: results from the Prostate Cancer Outcomes Study. , 2001, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[8]  L. Fried,et al.  Frailty in older adults: evidence for a phenotype. , 2001, The journals of gerontology. Series A, Biological sciences and medical sciences.

[9]  D. Schoenfeld,et al.  Effects of Testosterone and Progressive Resistance Training in Eugonadal Men with AIDS Wasting , 2000, Annals of Internal Medicine.

[10]  P. Stone,et al.  Fatigue in patients with prostate cancer receiving hormone therapy. , 2000, European journal of cancer.

[11]  H. Herr,et al.  Quality of life of asymptomatic men with nonmetastatic prostate cancer on androgen deprivation therapy. , 2000, The Journal of urology.

[12]  G. Beall,et al.  Testosterone replacement and resistance exercise in HIV-infected men with weight loss and low testosterone levels. , 2000, JAMA.

[13]  J. Berlin,et al.  Effect of testosterone treatment on body composition and muscle strength in men over 65 years of age. , 1999, The Journal of clinical endocrinology and metabolism.

[14]  R. Casaburi,et al.  Testosterone replacement increases fat-free mass and muscle size in hypogonadal men. , 1997, The Journal of clinical endocrinology and metabolism.

[15]  D. Schoenfeld,et al.  Increase in bone density and lean body mass during testosterone administration in men with acquired hypogonadism. , 1996, The Journal of clinical endocrinology and metabolism.

[16]  N. Ancy,et al.  The effects of supraphysiologic doses of testosterone on muscle size and strength in normal men. , 1996 .

[17]  F. Pi‐Sunyer,et al.  Health implications of obesity. , 1991, The American journal of clinical nutrition.

[18]  D. Heber,et al.  Nutritional and metabolic effects of gonadotropin-releasing hormone agonist treatment for prostate cancer. , 1990, Metabolism: clinical and experimental.

[19]  P. Goodman,et al.  Leuprolide With and Without Flutamide in Advanced Prostate Cancer , 1990, Cancer.

[20]  W R Foster,et al.  Health implications of obesity: an NIH Consensus Development Conference. , 1985, Journal of the American Dietetic Association.

[21]  N. Shahidi.  Androgens and erythropoiesis. , 1973, The New England journal of medicine.

[22]  J. Kaufman,et al.  Testosterone, body composition and aging. , 1999, Journal of endocrinological investigation.